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An Estimator Of Intervention Effect On Disease Severity 
 
David Siev 
USDA Center for Veterinary Biologics 
 
 
When a medical intervention prevents a dichotomous outcome, the size of its effect is often estimated 
with the prevented fraction. Some interventions may reduce the severity of an outcome without entirely 
preventing it. To quantify the effect of a severity-moderating intervention, a measure termed the mitigated 
fraction (MF) is proposed. MF has broad applicability, because it measures the overlap of two empirical 
distributions based on their stochastic ordering. It is also useful in the specific context of medical 
interventions, because it shares certain structural and functional features with the prevented fraction. The 
two measures may be applied together in a single semiparametric model with components for outcome 
prevention and for severity conditional on the presence of the outcome. 
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Introduction 
 
When a medical intervention is intended to 
prevent a dichotomous outcome, such as the 
presence or absence of disease, an estimator 
known as the prevented fraction (PF) is 
commonly used to measure its effect. Vaccine 
efficacy, for example, is often estimated using 
some form of prevented fraction. Some 
interventions are, however, intended to reduce 
disease severity without entirely preventing 
disease. It would be valuable to have an 
estimator that is broadly applicable for 
evaluating vaccine efficacy in reducing disease 
severity (Mehrotra, 2004). An estimator that has 
proved useful in animal vaccine studies is the 
mitigated fraction (MF). The mitigated fraction 
is a new incarnation of an old statistic with a 
number of salient attributes. It is both analogous 
in function and homologous in structure to the 
prevented fraction.  
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 For vaccination, PF is the relative 
decrease in the probability a vaccinate will 
become a case, while MF is the relative increase 
in the probability that a vaccinate’s disease will 
be less severe than a nonvaccinate’s disease. 
This article shows its origin, describes some of 
its features, and illustrates how PF and MF may 
be components of a nested model.  
 
Example 
 A swine respiratory disease vaccine 
study included groups of pigs treated with either 
vaccine or placebo. All subjects were exposed to 
the pathogen and subsequently sacrificed. At 
postmortem examination, the extent of gross 
lesions in the lungs of each subject was 
estimated by visual approximation. Two 
observers independently sketched on a grid the 
dorsal and ventral surfaces of each of the seven 
lung lobes. The fraction of each lobe was taken 
as the average of the two surfaces and two 
observers. The lobe fractions were weighted (by 
their standard relative mass) and summed to 
arrive at the fraction of the lungs consisting of 
gross lesions. They are shown in Figure 1.  
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Figure 1. Fraction of lungs consisting of gross 
lesions. Number of subjects – placebo: 21, 
vaccine: 22. Points are jitter vertically to aid 
visualization. 
  
 
 
 How then should one analyze and 
summarize the findings of this study? The 
subjects could be divided into unaffected (0% 
lesions) and affected (more than 0% lesions). 
The prevented fraction could then be estimated, 
using methods for binary data. Important 
information is lost, however, if one only 
considers whether the response was present or 
absent and ignores its severity, particularly 
because most subjects were affected, and there 
was a wide range of response. 
 An approach often seen with this type of 
data is to calculate the average percent in each 
group and compare the group averages by their 
difference or relative difference. Taking 
averages is not the soundest way to summarize 
data that are highly skewed and border a 
boundary of the parameter space. The resulting 
summary measure also does not illuminate the 
vaccine’s impact on individual subjects, as does 
PF, which is the relative decrease in the 
probability a vaccinate will become a case. A 
measure analogous to PF is MF, the relative 
increase in the probability that a vaccinate’s 
disease will be less severe than a nonvaccinate’s 
disease. An interesting question is whether to 
estimate MF for the entire set of data, or only for 
those affected by challenge. That point will be 
considered further when the example is 
revisited. 
 
 
Mitigated Fraction  
 Prevented fraction has the general 
form 2 11PF p p= − , where, say, p1 is the 
expected fraction of nonvaccinates affected by 
disease, and p2 is the corresponding expectation 
among vaccinates.  As the usual estimator of 
vaccine effect, PF is often simply termed 
vaccine efficacy (VE) in vaccine studies. Besides 
binomial expectations, VE may be constructed 
from other parameters that are related in some 
way to the probability of disease transmission 
(see Table 1 of Halloran et al., 1997, for an 
overview). 
 Suppose that all subjects in a vaccine 
trial become sick, whether vaccinated or not. 
Rather than looking at the effect of vaccination 
on the relative probability of contracting the 
disease, one might now wish to consider the 
effect of vaccination on the relative probability 
that the disease is milder. An estimator may be 
constructed that is both analogous to PF in 
function (summarizing subject probabilities) and 
homologous to PF in structure (difference 
relative to nonintervention). 
 To highlight these features, it is called 
the mitigated fraction (MF). That is, 
2 01MF t t= −  where t2 is the estimated 
probability that a vaccinate’s disease is more 
severe than that of a nonvaccinate, and t0 is the 
probability of greater severity in the absence of 
vaccination. MF may range from -1 to 1, unlike 
PF, which can take any real value no greater 
than 1. The difference in their ranges is related 
to the fact that the constituent probabilities in 
MF are relative (more or less severe than the 
other treatment group), while those in PF are not 
(presence or absence of disease). In practice, if a 
vaccine does not actually cause disease, both 
MF and PF will take values from 0 to 1.  
 If disease severity can be graded by 
some continuous measure or discrete assessment 
in a way that results in unambiguous ranks, the 
mitigated fraction is estimated by 
 
{ }1 1 1 2 1 22 (1 )M F W n n n n n= − + +  
 
where W is the familiar Wilcoxon rank sum 
statistic, n is the number of subjects in a group, 
and the subscripts are 1 for nonvaccinates and 2 
for vaccinates.  
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Background 
 A general problem is how to distinguish 
between samples of two populations in some 
quantifiable way that avoids all parametric 
assumptions. A useful approach is to consider 
the stochastic ordering of the two empirical 
distributions. Figure 2 illustrates two estimators 
that do so, 
1
2P rob( ) P rob( )i i j i jT Y Y Y Y= > + = . 
 For continuous random variables 
Prob(Yi = Yj) = 0, of course, and the second term 
is omitted from the figure label for simplicity, 
but without loss of generality. If two 
distributions are stochastically identical, the 
probability that a realization from one of them is 
greater or lower than a realization from the other 
is one half. Consequently, iθ  rescales Ti to range 
from –1 to 1, with 0 corresponding to the null 
probability, ½. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Because Ti and Tj are complementary 
probabilities, summing to one and equidistant 
from ½, iθ  may be reformulated as 
 
( ) ( )
i i j
j i j i
T T
P Y Y P Y Y
θ = −
= < − >
 
 
 In other words, iθ  is a measure of the 
overlap between the two distributions based on 
their stochastic ordering. A general measure of 
the overlap of two distributions is simply θ , the 
absolute value of either iθ . ( )122i Tθ θ= = − , 
where  
 
{ }1 2 1 2sup Prob( ), Prob( )T y y y y= > < . 
 
θ  is used when comparing distributions that 
have no particular relative ordering. iθ , on the 
other hand, is useful when the distributions arise 
in a particular setting that establishes an ordered 
relationship. For example, population 2 may be 
manifesting the effect of a medical intervention 
that is being compared to population 1, 
representing placebo treatment. 
 These estimators are generalizations of 
known statistics. For example, mean ridits 
(Bross, 1958) are Ti, and Somers’ d statistics 
(Somers, 1962) are iθ . (Vigderhous (1979) 
noted the connection between ridits and Somers’ 
d). Somers’ d was conceived as a measure of 
association between two ordinal variables, in 
contrast to ridit analysis, which was designed to 
compare the distributions of an ordinal variable 
in each of two distinct populations. Here, they 
are generalized to encompass data of all types 
that are not necessarily categorical and may arise 
from independent or correlated distributions. 
This general approach has been advocated by 
other authors (Wolf & Hogg, 1971). 
 It is well known that an estimate of T 
may be recovered from the Wilcoxon-Mann-
Whitney statistic (Wolf & Hogg, 1971, equation 
1). That may be done as follows.  
 
( 1) 2i i i i
i
i j i j
U W n nT
n n n n
− +
= =  
 
where 
 
Wi = sum of the ranks in group i (the 
Wilcoxon rank sum statistic), and Ui = 
number of times a yjk precedes a yih (the 
Mann-Whitney U statistic), i.e., 
 
1 1
H( , )
j in n
i jk ih
k h
U y y
= =
=
∑∑
, 
 
where 
 
1
2( , ) 1if ; 0if ; and ifa b a b a b a bΗ = < > = , 
and yih is the response of subject h (h = 1 ... 
ni) in group i (i = 1, 2). 
 
 
–1 0 1
0 1½
( )Probi i jT y y= >
( )122i iTθ = −
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Substituting ( )122i iTθ = −  gives  
 
{ }2 (1 )i i i i j i jW n n n n nθ = − + +  
 
Stratified Design  
 To estimate θ  from stratified data use 
i ir ir jr
r r
T U n n=
∑ ∑
, where r indexes the strata. 
For matched pairs, this reduces to a simple 
binomial fraction I( )i jr ir
r
T y y R= <
∑
, where 
R is the number of pairs and I( )i  is the indicator 
function. In that case, interval estimation can 
proceed by familiar methods for binomial 
fractions. 
 
Subject Components  
MF may be decomposed into the 
contribution of individual subjects. The 
component for a vaccinated subject j is 
1
2 1
11
2 H( , ) 1
n
j j k
k
s y y
n
=
= −
∑
, which is its 
contribution to 
2
12
1 n
j
j
MF s
n
=
=
∑
. MF is thus the 
mean of the individual subject components.  
 
Confidence Intervals 
 Confidence intervals using normal 
approximations can be derived from the 
asymptotic variance for W or the asymptotic 
variance for Somers’ d provided by popular 
software packages. Such intervals depend on 
assumptions are preferably avoided and may 
even contain inadmissable values. An alternative 
is to calculate confidence intervals for MF by 
one of the bootstrap methods (Efron & 
Tibshirani, 1993); this is an area of ongoing 
investigation. 
 
 
 
 
 
 
 
 
 
 
Graphical Representation (Example) 
 Figure 3 shows the empirical cumulative 
distribution function of the difference 
distribution, 2 1( )F Y Y− , obtained from taking all 
pairwise differences between the groups in our 
example: 2 1ij i jd y y= − , where 21,...,i n=  and 
11,...,j n= . The arrow leading from the 50% 
quantile indicates the median difference (the 
Hodges-Lehmann estimator), which gives some 
idea of the amount of shift between the two 
distributions. The quantile corresponding to a 
difference of zero is the probability that a 
vaccinate’s disease is less severe than that of a 
nonvaccinate (T1). Rescaling the difference 
between T1 and the median gives MF, shown in 
the right hand y axis. MF is thus a rescaled 
quantile of the difference distribution.  
 In contrast to the median difference, 
which is in the original units of measurement on 
the abscissa (x axis), MF reflects probabilities on 
the ordinate (y axis). In this example, T1 = 0.69 
means that 69% of the nonvaccinates are 
expected to be more severely affected than the 
vaccinates,  ( )1212 0.39MF T= − = , (95%  boot- 
strap CI: 0.06 to 0.68). The vaccine benefited an 
estimated 39% of the 50% of vaccinates who, in 
the absence of vaccination, would have been 
more severely affected than nonvaccinates. 
 
Interpretation and application of MF 
MF is the increase due to vaccination of 
the probability that a vaccinate’s disease will be 
less severe than a nonvaccinate’s disease, 
relative to the probability that it would have 
been less severe had the individual not been 
vaccinated. It is important to avoid direct 
comparison between PF and MF, which have 
somewhat different implications. Many of the 
usual estimators of vaccine efficacy are 
concerned with the prevention of outcomes that 
AN ESTIMATOR OF INTERVENTION EFFECT ON DISEASE SEVERITY 
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are links in the chain of disease transmission, 
such as infection or infectivity, and in this 
respect MF is not like them. PF also relies on 
explicit case definitions, while MF is intended 
for situations where disease severity need only 
be clearly graded.  
 MF is analogous to PF in that it is based 
on estimated subject probabilities. Some relative 
difference measures that attempt to mimic PF in 
formulation may not necessarily have an 
analogous implication and should be interpreted 
cautiously. For example, a formulation that is 
often used to emulate PF is the relative 
difference of means ( 1 2 1( )y y y− ). This is, at 
best, a comparison of population averages rather 
than subject distribution. It is rarely appropriate 
as the sole assessment of vaccine efficacy when 
the outcome is continuous rather than 
dichotomous (and it is particularly misleading 
when the data may not have arisen from a 
location-scale distribution). Although such 
estimators may be devised to emulate the 
configuration of PF, they fail to capture a 
similar meaning, since what is important about 
the constituent parameters in PF is not that they 
are means but that they are category 
probabilities. In this respect, MF is an estimator 
that is analogous to PF.  
 The use of mean based estimators may 
also arise from an understandable desire to 
quantify the amount of severity reduction. 
Unfortunately, such estimators are sensitive to 
the form and scale of the response measurement, 
which may vary substantially between similar 
studies. MF, on the other hand, is invariant to 
order-preserving transformations of the data. 
The price for such invariance is that MF gives 
no information about the magnitude of disease 
severity reduction, and a large value of MF may 
result from a small but highly probable reduction 
 
 
 
 
Difference (y2 – y1) in Lung Fraction 
Median = –0.07 
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Figure 3.  Empirical difference distribution showing MF as a rescaled quantile. 
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in severity. That is why it is a good idea to 
accompany MF with an estimator in the original 
units of measurement, such as the empirical 
quartiles illustrated in Figure 1. 
 MF may also be estimated under a range 
of parametric assumptions, thereby offering a 
common approach to studies of various types. 
The example illustrates its most general 
application, where there are no assumptions 
other than that the data are legitimately ranked. 
MF could just as readily be estimated from 
ordinal categories or continuous data. With 
categorical data, the estimator based on W 
corresponds to the ridit estimator. In parametric 
analyses, the probabilities are obtained from the 
estimated cumulative distribution functions. For 
example, the frequency table shows the number 
of subjects of a drug trial in categories of 
increasing disease severity. (The data are a 
subset of those analyzed by Poon (2004).) By 
the formula, estimated MF = 0.08 (95% 
bootstrap CI: -0.07, 0.23). By Poon’s latent 
normal model, estimated MF = 0.10 (95% 
profile likelihood CI: -0.11, 0.30). Regardless 
how the probabilities are estimated, the meaning 
of MF remains the same. 
 
 
 
 
Conditional MF in Nested Models 
 
Nested Model 1 
 Consider a model with a component for 
the presence or absence of disease and a 
component for disease severity among only 
those who become sick. Suppose resistance to 
the pathogen is dichotomous, while the immune 
response to vaccination among those susceptible 
to challenge follows some discrete or continuous 
distribution. Such a model may be formulated 
 
[ ]1( ) (1 ) ( | 0) ddf y f y yπ π −= − > , 
 
where I( 0)d y= = (i.e. d is an indicator taking 
the value 1 if y=0 and 0 otherwise) and 
( )E dπ = , its expectation. The likelihood is then 
factored into a Bernoulli likelihood and a 
conditionally independent part which contributes 
to the total only for responders. This is a nested 
model with conditionally independent 
components. Since participation in the second 
part is conditional on crossing the hurdle of the 
first part, this type of nested model is sometimes 
termed a hurdle model (Mullahy, 1986).  
 If ( | 0)f y y >  were completely 
specified, say as a beta density, maximum 
likelihood estimation could be used to assess 
how the treatment groups differed with respect 
to prevention, conditional severity, or both. If 
complete specification is not warranted, PF may 
be estimated from the first part and MFC , the 
conditional mitigated fraction among those 
affected, from the second part. To do so, let  
 
1i ip π= −  
 
and 
 
| 0, 0Ci i i jT T y y= > > . 
 
Then, 
 
2 11PF p p= − and 12 1CCMF T= − . 
 
 The conditionally independent nature of 
the nested components distinguishes the nested 
model from more complex mixture models. For 
example, continuous data with many zeros 
would, in some cases, be analyzed with a zero-
inflated model. In contrast to a nested model, the 
nonresponse portion of a zero-inflated model 
describes a latent mixture of two populations, 
one which may be incapable of response and 
another capable of response but with response 
zero according to distribution ( )Yf y , leading to 
the formulation  
 
{ } [ ]1( ) (1 ) (0) (1 ) ( | 0) ddY Yf y f f y yλ λ λ −= + − − > , 
 
where λ  is the population mixture parameter.  
 An example of a nested model for 
categorized data is the well-known continuation-
ratio factorization of the multinomial likelihood 
increasing disease severity → 
placebo 2 22 54 29 3 
drug 4 23 45 22 2 
AN ESTIMATOR OF INTERVENTION EFFECT ON DISEASE SEVERITY 
 
506 
into conditionally independent binomial 
components. It may be parameterized 
1
( ) (1 )j j
J
y n r
j j
j
L π δ δ −
=
∝ −∏ , where, for the jth of 
J categories, jy is the category count, jπ  is the 
category probability, 1jk kjr y== ∑  is the 
cumulative category count, and 1Jj jn y== ∑ is the 
total. 
 The continuation ratios are 
J
j j kk jδ π π== ∑ , the probability of being in 
category j given not in any previous category. 
Continuation-ratio models are useful for 
tabulated health events that occur in a natural 
sequence. For example, the impact of a pathogen 
on reproductive health may be seen by the 
presence of normal conception, gestation, 
parturition, and neonatal vigor, and a subject’s 
inclusion at any stage depends on successfully 
passing the previous stage. Continuation-ratio 
models may also be applied to ordinal 
categories, such as disease severity, if they are 
similarly considered to be nested. In some 
situations they may offer an alternative to the 
more common cumulative probability models.  
 Suppose disease is categorized as 
absent, mild, moderate, and severe, and the 
counts for the two groups are arrayed in a 4 x 2 
contingency table. MF could be estimated from 
the entire table, or separate estimates could be 
obtained for PF and MFC. PF would be 
estimated from the 2 x 2 table collapsing over 
categories 2 through 4, while MFC would be 
estimated from the 3 x 2 table that excludes the 
first category. A similar rationale could be 
applied to ranked data if each rank were thought 
to represent a discrete category. 
 
Implications of Nested Model   
 What are the implications of the nested 
model for prevention and conditional severity? 
Suppose all nonvaccinates are sick while some 
vaccinates are unaffected ( 1 21, 1p p= < ), and 
disease severity is reduced among the 
vaccinates. MF is then a simple function of its 
components: 1 (1 )(1 )CM F M F PF= − − − . 
Otherwise, in most practical situations where the 
vaccine both prevents disease ( 0PF > ) and 
reduces its severity among those affected 
( 0CMF > ), the relationship would be 
1 (1 )(1 )CMF MF PF< − − − . If the vaccine 
reduces disease severity among the affected but 
has no effect on disease prevention, although 
resistant individuals are found among both 
nonvaccinates and vaccinates ( 1 2 1p p= < ), the 
inequality reduces to CMF MF< . In both latter 
situations, MFC and PF provide illuminating 
information and may be examined separately 
from MF. On the other hand, in the unlikely but 
not impossible case that the vaccine were to 
prevent disease but increase severity among 
affected vaccinates ( 0CMF < ), MF could be a 
useful summary which balances the benefit of 
prevention against the detriment of increased 
severity. 
 
Nested Model 2 
 Nested models may also be constructed 
when the first component is at the end, rather 
than the beginning, of the disease process. For 
example, suppose participation in the evaluation 
of disease severity depends on whether or not a 
subject survives. The model would then be 
 
[ ] 1( ) ( | 0 ) (1 )x xf y f y x π π −= = − , 
 
where each observation consists of the pair 
{ },y x , y is the measurement of disease severity, 
and x takes the values 0 if the subject has died 
and 1 otherwise. 
 
Implications of Nested Model 2 
 What are the implications of the nested 
model for severity given that a terminal outcome 
has not occurred? Suppose a subject dies. Is its 
prior disease severity relevant? There are several 
possibilities. For example, in an established 
clinical model where the severity of gross 
lesions predicts a possibly fatal disease, it may 
be valid to include the observations of all 
subjects, surviving or not, to assess disease 
severity. On the other hand, there may be no 
clear association between the observation and 
disease. Acute death may occur in response to 
pathogen challenge without any clinical signs at 
all. Retaining the observations of the dead 
SIEV 507 
subjects when the severity measure is unrelated 
to a primary clinical outcome perpetuates an 
incoherent clinical model. In such cases, rank 
based methods are sometimes applied after 
assigning the dead subjects a common value 
greater than the maximum value of the surviving 
subjects. This approach treats death as simply 
the severest manifestation of disease, ignoring 
the qualitative difference between death and 
survival. A third position is that death is a 
critical event, but the prior disease severity of 
dead subjects is of no practical interest, leading 
us to exclude them from the evaluation of 
disease severity, but including all subjects when 
considering mortality. Since participation in 
disease severity evaluation is conditional on 
survival, a nested model may be constructed in 
which each observation consists of the pair 
{ },y x , where x indicates whether or not the 
subject has died, and y is the measurement of 
disease severity (nested model 2). 
 
Example revisited 
In the swine vaccine example, an 
estimate of the mitigated fraction is 
0.39MF = (95% bootstrap CI: 0.06 to 0.68). 
(The asymptotic approximation is 0.07, 0.71.) A 
number of subjects in the study did not succumb 
at all to pathogen challenge. Suppose resistance 
to the pathogen is dichotomous, while the 
immune response to vaccination among those 
susceptible to challenge follows some 
continuous distribution. The dichotomous 
response may be described by PF, and the 
continuous response by MFC , the conditional 
mitigated fraction among those affected. PF and 
MFC would be derived from the conditionally 
independent components of a hurdle model 
(nested model 1). 
The value of nested models is that they 
allow simultaneous inference on two 
components that are conditionally independent. 
In the example, one would estimate PF by 
categorizing all observations as disease positive 
if the pathological lung fraction is greater than 
zero and disease negative otherwise. MFC is then 
estimated using only the nonzero observations. 
Taking that approach, point and interval 
estimates are 0.21PF =  (-0.15, 0.49), and 
0.42CMF =  (0.01, 0.49). Apparently, the study 
is insufficient for conclusive inference on either 
one alone. 
 
Conclusion 
 
Although it is easily calculated from the 
Wilcoxon statistic, MF is aimed at estimation 
rather than hypothesis testing. Consequently, it 
helps focus attention on the clinical relevance of 
the outcome. Nonparametric tests are sometimes 
abused by those who seem to think that avoiding 
certain parametric assumptions also eliminates 
the need for forethought in study design. Care is 
particularly needed when observations are 
recorded in the form of derived ratings such as 
complex scoring schemes which, unlike simple 
grading scales, often do not preserve a clear 
correspondence of score with disease severity. 
Unless one is confident in the scores' validity 
when ranked, the methods shown here should 
not be used. Nonparametric analysis will not 
salvage a poorly designed scoring scheme. 
 Estimation requires an outcome that is 
quantitatively meaningful as well as clinically 
relevant. The study protocol should explicitly 
specify the outcome variable and describe how it 
will be recorded. Outcome specification should 
also aim to highlight the random structure of the 
data rather than conceal or ignore it by appeal to 
rank based methods. 
 For this reason, the use of nonparametric 
techniques in pivotal confirmatory studies has 
been discouraged (e.g. Longford and Nelder, 
1999). Critics point out that reliance on 
nonparametric methods may simply postpone 
the search for a suitable scale of measurement 
and clarification of its stochastic nature, which 
are prerequisites for planning a study able to 
yield informative estimates of the size and 
uncertainty of relevant effects. Full 
distributional specification of a germane 
response variable is certainly ideal. 
Nevertheless, the basis of MF on ranks gives it 
the very qualities that are valuable in certain 
types of studies, particularly where a measure 
based on subject probabilities is preferable to an 
alternative measure formed from averages.  
 Because the mitigated fraction is 
comparable in structure and function to the 
prevented fraction, it is a useful method of 
estimating the benefit of an intervention that 
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reduces disease severity. Like PF, MF evaluates 
the intervention’s effect by the probability a 
subject will benefit from the intervention. For 
this reason, MFC and PF may illuminate 
different aspects of the same intervention when 
they are components of a nested model, and MF 
may be useful in comparisons between studies. 
For example, animal vaccine studies typically 
entail challenging all subjects with the virulent 
pathogen. The response to challenge often varies 
in magnitude between studies, and, when the 
response is an uncategorized measure of disease 
severity, the relative difference between mean 
group responses often varies, as well. While it is 
difficult to completely standardize the evaluation 
of such studies, MF estimates the probability of 
a beneficial response to vaccination, offering a 
way to assess the degree of vaccine effect at 
different times or locations. 
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